# NRG-GU008 (NCT04134260)

> Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

No report yet. It can be ordered.

- Drugs tested: apalutamide
- Indication: node-positive prostate cancer after radical prostatectomy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04134260
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: NRG Oncology
- Conditions: Prostate Adenocarcinoma; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
- Interventions: Apalutamide; Biospecimen Collection; Bone Scan; Computed Tomography; Hormone Therapy; Magnetic Resonance Imaging; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy
- Enrollment: 586
- Primary outcome: Metastasis-free survival (MFS)

## Indexed commentary on NRG-GU008 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X
- 4 YouTube videos

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nrg-gu008-nct04134260

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04134260", "email": "<work email>"}; the inbox owner confirms by the emailed link.